Sonia Saxena1, Christina Atchison2, Elizabeth Cecil2, Mike Sharland3, Elizabeth Koshy2, Alex Bottle2. 1. Department of Primary Care and Public Health, Imperial College London, W6 8RF, UK. Electronic address: s.saxena@imperial.ac.uk. 2. Department of Primary Care and Public Health, Imperial College London, W6 8RF, UK. 3. Paediatric Infectious Diseases Unit, St George's Hospital NHS Trust, London SW17 0QT, UK.
Abstract
OBJECTIVES: A wider spectrum 13-valent pneumococcal vaccine (PCV13) replaced PCV7 in the child immunization schedule in England from 2010. We assessed the additional impact of PCV13 over PCV7 on all-cause pneumonia and empyema admissions. METHODS: We extracted Hospital Episode Statistics data from 2001 to 2014 on all-cause pneumonia (ICD-10 codes J12-18) and empyema admissions (J86.0, J86.9) for children <16 years in England. Trend analysis and rate ratios (RR) were calculated comparing the Pre-vaccine era to September 2006, the PCV7 era and the PCV13 era from April 2010. RESULTS: Annual hospital admissions for pneumonia and empyema were increasing in the Pre-vaccine era peaking in 2005 at 15,733 pneumonia and 382 empyema cases (158.6 and 3.9 per 100,000 children, respectively). These rates fell following PCV7 introduction in 2006 but began to climb soon afterwards until PCV13 was introduced. By 2013, admission rates for pneumonia and empyema were 102.2 and 1.9 per 100,000 children, respectively. We found no added benefit of PCV13 over PCV7 on pneumonia admissions following PCV13 introduction but there was a significant decrease in empyema admissions in children aged <2 years (RR 0.58; 95% CI 0.34-0.99). CONCLUSIONS: Additional serotypes covered by PCV13 may be more important in the aetiology of empyema and invasive disease than as a cause of uncomplicated pneumonia.
OBJECTIVES: A wider spectrum 13-valent pneumococcal vaccine (PCV13) replaced PCV7 in the child immunization schedule in England from 2010. We assessed the additional impact of PCV13 over PCV7 on all-cause pneumonia and empyema admissions. METHODS: We extracted Hospital Episode Statistics data from 2001 to 2014 on all-cause pneumonia (ICD-10 codes J12-18) and empyema admissions (J86.0, J86.9) for children <16 years in England. Trend analysis and rate ratios (RR) were calculated comparing the Pre-vaccine era to September 2006, the PCV7 era and the PCV13 era from April 2010. RESULTS: Annual hospital admissions for pneumonia and empyema were increasing in the Pre-vaccine era peaking in 2005 at 15,733 pneumonia and 382 empyema cases (158.6 and 3.9 per 100,000 children, respectively). These rates fell following PCV7 introduction in 2006 but began to climb soon afterwards until PCV13 was introduced. By 2013, admission rates for pneumonia and empyema were 102.2 and 1.9 per 100,000 children, respectively. We found no added benefit of PCV13 over PCV7 on pneumonia admissions following PCV13 introduction but there was a significant decrease in empyema admissions in children aged <2 years (RR 0.58; 95% CI 0.34-0.99). CONCLUSIONS: Additional serotypes covered by PCV13 may be more important in the aetiology of empyema and invasive disease than as a cause of uncomplicated pneumonia.
Authors: Sana S Ahmed; Fernanda C Lessa; Hilma Coradin; Jacqueline Sánchez; Maria da G Carvalho; Elizabeth Soda; Chabela Peña; Josefina Fernández; Doraliza Cedano; Cynthia G Whitney; Jesús Feris-Iglesias Journal: J Infect Dis Date: 2021-09-01 Impact factor: 7.759
Authors: Grant A Mackenzie; Philip C Hill; Shah M Sahito; David J Jeffries; Ilias Hossain; Christian Bottomley; Uchendu Uchendu; David Ameh; Malick Ndiaye; Chidebereh D Osuorah; Oyedeji Adeyemi; Jayani Pathirana; Yekini Olatunji; Bade Abatan; Ebirim Ahameefula; Bilquees S Muhammad; Augustin E Fombah; Debasish Saha; Roslyn Mackenzie; Ian Plumb; Aliu Akano; Bernard Ebruke; Readon C Ideh; Bankole Kuti; Peter Githua; Emmanuel Olutunde; Ogochukwu Ofordile; Edward Green; Effua Usuf; Henry Badji; Usman N A Ikumapayi; Ahmad Manjang; Rasheed Salaudeen; E David Nsekpong; Sheikh Jarju; Martin Antonio; Sana Sambou; Lamin Ceesay; Yamundow Lowe-Jallow; Dawda Sowe; Momodou Jasseh; Kim Mulholland; Maria Knoll; Orin S Levine; Stephen R Howie; Richard A Adegbola; Brian M Greenwood; Tumani Corrah Journal: Lancet Infect Dis Date: 2017-06-07 Impact factor: 25.071
Authors: Arto A Palmu; Hanna Rinta-Kokko; Hanna Nohynek; J Pekka Nuorti; Terhi M Kilpi; Jukka Jokinen Journal: PLoS One Date: 2017-03-01 Impact factor: 3.240
Authors: Daniel James Hungerford; Neil French; Miren Iturriza-Gómara; Jonathan M Read; Nigel A Cunliffe; Roberto Vivancos Journal: J Epidemiol Community Health Date: 2019-09-11 Impact factor: 3.710